Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00261391 · ClinicalTrials.gov registry record · Phase 1
Phase I Drug Trial for S/E of Marimastat in Disabling Malformations When no Other Options.
A Phase 1 study of Vascular Anomalies, sponsored by Boston Children's Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT00261391 is a Phase 1 study of Vascular Anomalies that has completed, run by Boston Children's Hospital. The registered enrollment target is 9 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00261391, a Phase 1 study of Vascular Anomalies, has completed, sponsored by Boston Children's Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
3 patients were enrolled in each of 3 study cohorts. There three cohorts were given differing, incrementally larger doses of this phase I drug. The same safety measures are being obtained on all patients. Efficacy measures were individualized as enrolllees do not have the same underlying vascular anomaly. The study is structured to include a 24 month drug-phase and a 24 month follow-up phase. The study is now closed to enrollment.
Conditions Studied
Interventions
- DRUG Marimastat
Study Locations (1)
Massachusetts
- Childrens Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2000-10 |
| Est. Completion | 2007-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00261391
The ClinicalTrials.gov registry entry for NCT00261391 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Vascular Anomalies appearing as the primary indexed condition, and to 1 intervention - of which Marimastat is the first listed.
NCT00261391 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00261391 about?
NCT00261391 is a clinical study titled "Phase I Drug Trial for S/E of Marimastat in Disabling Malformations When no Other Options.". 3 patients were enrolled in each of 3 study cohorts. There three cohorts were given differing, incrementally larger doses of this phase I drug. The same safety measures are being obtained on all patients. Efficacy measures were individualized as enrolllees do not have the same underlying vascular an...
What is the current status of trial NCT00261391?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2000-10. Estimated completion is 2007-10.
What conditions does trial NCT00261391 study?
This clinical trial studies the following conditions: Vascular Anomalies.
What interventions are being tested in trial NCT00261391?
The interventions under investigation include: Marimastat (DRUG).
Who is sponsoring clinical trial NCT00261391?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00261391 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.